TKToshiaki Kikuchi

Toshiaki Kikuchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Toshiaki Kikuchi has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Toshihiro Nukiwa

    Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, 2Department of Microbiology and Immunology, Graduate School of Medicine, and 3Division of Microbiology and Immunology, Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Tohoku University, Sendai, Japan. 4Laboratory for Immune Regulation, RIKEN Research Center for Allergy and Immunology, Yokohama, Japan

    7 shared publications
  • Sita Andarini

    University of Indonesia

    4 shared publications
  • Yasuo Saijo

    Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, 2Department of Microbiology and Immunology, Graduate School of Medicine, and 3Division of Microbiology and Immunology, Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Tohoku University, Sendai, Japan. 4Laboratory for Immune Regulation, RIKEN Research Center for Allergy and Immunology, Yokohama, Japan

    4 shared publications
  • Jamal Zaini

    Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan Hospital National Respiratory Center, Jakarta, Indonesia

    3 shared publications
  • Naoto Ishii

    Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan

    3 shared publications
  • Takuji Suzuki

    Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan

    3 shared publications

Latest Publications

  • Open Access

    OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy

    by Ichiyo Shibahara, Ryuta Saito, Rong Zhang, Masashi Chonan, Takuhiro Shoji, Masayuki Kanamori, Yukihiko Sonoda, Toshihiro Kumabe, Masahiko Kanehira, Toshiaki Kikuchi, et al.

    Glioblastoma is the most malignant human brain tumor and has a dismal prognosis; however, some patients show long-term survival. The interaction between the costimulatory molecule OX40 and its ligand OX40L generates key signals for T-cell activation. The augmentation of this interaction enhances antitumor immunity. In this present study, we explored whether OX40 signaling is responsible for antitumor adaptive immunity against glioblastoma and also established therapeutic antiglioma vaccination therapy. Tumor specimens were obtained from patients with primary glioblastoma (n = 110) and grade III glioma (n = 34). Quantitative polymerase chain reaction (PCR), flow cytometry, and immunohistochemistry were used to analyze OX40L expression in human glioblastoma specimens. Functional consequences of OX40 signaling were studied using glioblastoma cell lines, mouse models of glioma, and T cells isolated from human subjects and mice. Cytokine production assay with mouse regulatory T cells was conducted under hypoxic conditions (1.5% O2). OX40L mRNA was expressed in glioblastoma specimens and higher levels were associated with prolonged progression-free survival of patients with glioblastoma, who had undergone gross total resection. In this regard, OX40L protein was expressed in A172 human glioblastoma cells and its expression was induced under hypoxia, which mimics the microenvironment of glioblastoma. Notably, human CD4 T cells were activated when cocultured in anti-CD3-coated plates with A172 cells expressing OX40L, as judged by the increased production of interferon-γ. To confirm the survival advantage of OX40L expression, we then used mouse glioma models. Mice bearing glioma cells forced to express OX40L did not die during the observed period after intracranial transplantation, whereas all mice bearing glioma cells lacking OX40L died. Such a survival benefit of OX40L was not detected in nude mice with an impaired immune system. Moreover, compared with systemic intraperitoneal injection, the subcutaneous injection of the OX40 agonist antibody together with glioma cell lysates elicited stronger antitumor immunity and prolonged the survival of mice bearing glioma or glioma-initiating cell-like cells. Finally, OX40 triggering activated regulatory T cells cultured under hypoxia led to the induction of the immunosuppressive cytokine IL10. Glioblastoma directs immunostimulation or immunosuppression through OX40 signaling, depending on its microenvironment.


  • Mycobacterial hypersensitivity pneumonitis requires TLR9–MyD88 in lung CD11b+ CD11c+ cells

    by H. Daito, T. Kikuchi, T. Sakakibara, K. Gomi, T. Damayanti, J. Zaini, N. Tode, M. Kanehira, S. Koyama, S. Fujimura, et al.

    Mycobacteria are among the most common causes of hypersensitivity pneumonitis (HP), but controversy persists with regard to the involvement of the infectious potency of the organism in mycobacterial HP (hot tub lung). This study aimed to establish a mouse model of hot tub lung to clarify its pathophysiology.Mice were exposed intranasally to formalin-killedMycobacterium aviumfrom a patient with hot tub lung (HP strain) or chronic pulmonary infection (non-HP strain), and bronchoalveolar lavage fluids and lung tissues were evaluated for allergic inflammation.DeadM. aviumHP strain, but not non-HP strain, elicited marked HP-like pulmonary inflammation in wild-type mice. Although the inflammation was induced in mice lacking CD4 or CD8, the induction of HP-like responses was prevented in mice lacking myeloid differentiation factor (MyD)88 or Toll-like receptor (TLR)9. Cultured lung CD11c+ cells responded toM. aviumin a TLR9-dependent manner, and reconstitution of TLR9-/- mice with lung CD11c+ cells from wild-type mice restored the inflammatory responses. Further investigation revealed that pulmonary exposure toM. aviumHP strain increased the number of lung CD11b+ CD11c+ cells (dendritic cells) through TLR9 signalling.Our results provide evidence that hot tub lung developsviathe mycobacterial engagement of TLR9–MyD88 signalling in lung CD11b+ dendritic cells independent of the mycobacterial infectious capacity.


    • 1 November 2010
      • Vol. 85  (11) , 809-13

    [Disease progression of Mycobacterium avium pulmonary infection and the mycobacterial variable number tandem repeat (VNTR) typing].

    by Toshiaki Kikuchi

    The disease progression of nontuberculous mycobacterial (NTM) pulmonary infection is variable, and it is sometimes difficult to distinguish between patients who require immediate therapy and those in whom such a decision can be withheld. Here we show that the progression of NTM lung disease due to Mycobacterium avium infection is significantly associated with the mycobacterial genotype. This suggests that genotyping of M. avium isolates may enable us to predict whether the lung disease will progress or not.

  • Open Access

    Association between mycobacterial genotypes and disease progression in Mycobacterium avium pulmonary infection

    by T Kikuchi, A Watanabe, K Gomi, T Sakakibara, K Nishimori, H Daito, S Fujimura, R Tazawa, A Inoue, M Ebina, et al.

    Background: Non-tuberculous mycobacterial lung disease, most commonly caused by Mycobacterium avium infection, tends to show variable disease progression, and significant disease predictors have not been adequately established. Methods: Variable numbers of tandem repeats (VNTR) were evaluated in 16 mycobacterial interspersed repetitive unit (MIRU) loci from M avium isolates cultured from respiratory specimens obtained from 2005 to 2007. Specifically, the association between VNTR profiles and disease progression was assessed. Results: Among the 37 subjects who provided positive respiratory cultures for M avium during the 2005–6 period, 15 subjects were treated within 10 months following a microbiological diagnosis of progressive M avium lung disease. Nine subjects underwent long-term follow-up (>24 months) without treatment for stable M avium lung disease. Based on a neighbour-joining cluster analysis used to classify M avium-positive subjects according to the VNTR profile, subjects with progressive versus stable lung disease were found to be grouped together in distinct clusters. Further analysis using logistic regression modelling showed that disease progression was significantly associated with the genetic distance of the M avium isolate from an appropriately selected reference (age-adjusted odds ratio 1.95; 95% confidence interval 1.16 to 3.30; p = 0.01 for the most significant model). A best-fit model could be used to predict the progression of M avium lung disease when subjects from the 2005–6 period were combined with those from 2007 (p = 0.003). Conclusion: Progressive lung disease due to M avium infection is associated with specific VNTR genotypes of M avium.


  • Open Access

    OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice

    by Jamal Zaini, Sita Andarini, Minoru Tahara, Yasuo Saijo, Naoto Ishii, Kazuyoshi Kawakami, Masaru Taniguchi, Kazuo Sugamura, Toshihiro Nukiwa, Toshiaki Kikuchi

    The exceptional immunostimulatory capacity of DCs makes them potential targets for investigation of cancer immunotherapeutics. We show here in mice that TNF-α–stimulated DC maturation was accompanied by increased expression of OX40 ligand (OX40L), the lack of which resulted in an inability of mature DCs to generate cellular antitumor immunity. Furthermore, intratumoral administration of DCs modified to express OX40L suppressed tumor growth through the generation of tumor-specific cytolytic T cell responses, which were mediated by CD4+ T cells and NKT cells. In the tumors treated with OX40L-expressing DCs, the NKT cell population significantly increased and exhibited a substantial level of IFN-γ production essential for antitumor immunity. Additional studies evaluating NKT cell activation status, in terms of IFN-γ production and CD69 expression, indicated that NKT cell activation by DCs presenting α-galactosylceramide in the context of CD1d was potentiated by OX40 expression on NKT cells. These results show a critical role for OX40L on DCs, via binding to OX40 on NKT cells and CD4+ T cells, in the induction of antitumor immunity in tumor-bearing mice.


  • Open Access

    Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors

    by Mio Nukiwa, Sita Andarini, Jamal Zaini, Hong Xin, Masahiko Kanehira, Takuji Suzuki, Tatsuro Fukuhara, Hiroyuki Mizuguchi, Takao Hayakawa, Yasuo Saijo, et al.

    Fractalkine (CX3CL1) is a unique membrane‐bound CX3C chemokine that serves as a potent chemoattractant for lymphocytes. The hypothesis of this study is that dendritic cells (DC) genetically modifiedex vivoto overexpress fractalkine would enhance the T cell‐mediated cellular immune response with a consequent induction of anti‐tumor immunity to suppress tumor growth. To prove this hypothesis, established tumors of different mouse cancer cells (B16‐F10 melanoma, H‐2b, and Colon‐26 colon adenocarcinoma, H‐2d) were treated with intratumoral injection of bone marrow‐derived DC that had been modifiedin vitrowith an RGD fiber‐mutant adenovirus vector expressing mouse fractalkine (Ad‐FKN). In both tumor models tested, treatment of tumor‐bearing mice with Ad‐FKN‐transduced DC gave rise to a significant suppression of tumor growth along with survival advantages in the treated mice. Immunohistochemical analysis of tumors treated with direct injection of Ad‐FKN‐transduced DC demonstrated that the treatment prompted CD8+T cells and CD4+T cells to accumulate in the tumor milieu, leading to activation of immune‐relevant processes. Consistent with the finding, the intratumoral administration of Ad‐FKN‐transduced DC evoked tumor‐specific cytotoxic T lymphocytes, which ensued fromin vivopriming of Th1 immune responses in the treated host. In addition, the anti‐tumor effect provided by intratumoral injection of Ad‐FKN‐transduced DC was completely abrogated in CD4+T cell‐deficient mice as well as in CD8+T cell‐deficient mice. These results support the concept that genetic modification of DC with a recombinant fractalkine adenovirus vector may be a useful strategy for cancer immunotherapy protocols.


  • Open Access

    Genetically Modified Dendritic Cells for Therapeutic Immunity

    by Toshiaki Kikuchi

    Dendritic cells are professional antigen presenting cells, which show an extraordinary capacity to initiate primary immune responses by stimulating T cells. This established function of dendritic cells has attracted much attention in efforts to develop useful vaccines for the treatment of cancer and infectious diseases. Designing effective strategies to generate clinical dendritic cell-based vaccine protocols remains a challenging field of research. The successful realization of immunotherapy utilizing dendritic cells will depend on modifications of these protocols to optimize the natural stimulatory properties of dendritic cells, such as genetic modification of dendritic cells. This review focuses on dendritic cell gene modifications for enhancing the multiple effector functions of dendritic cells, including viral and non-viral gene transfer into dendritic cells, and a variety of transferred genes, such as those encoding antigens, co-stimulatory molecules, cytokines, and chemokines.


  • Open Access

    Involvement of Fractalkine/CX3CL1 Expression by Dendritic Cells in the Enhancement of Host Immunity against Legionella pneumophila

    by Toshiaki Kikuchi, Sita Andarini, Hong Xin, Kazunori Gomi, Yutaka Tokue, Yasuo Saijo, Tasuku Honjo, Akira Watanabe, Toshihiro Nukiwa

    Legionnaires' disease is clinically manifested as severe pneumonia caused by Legionella pneumophila . However, the dendritic cell (DC)-centered immunological framework of the host defense against L. pneumophila has not been fully delineated. For this study, we focused on a potent chemoattractant for lymphocytes, fractalkine/CX3CL1, and observed that the fractalkine expression of DCs was somewhat up-regulated when they encountered L. pneumophila . We therefore hypothesized that fractalkine expressed by Legionella -capturing DCs is involved in the induction of T-cell-mediated immune responses against Legionella , which would be enhanced by a genetic modulation of DCs to overexpress fractalkine. In vivo immunization-challenge experiments demonstrated that DCs modified with a recombinant adenovirus vector to overexpress fractalkine (AdFKN) and pulsed with heat-killed Legionella protected immunized mice from a lethal Legionella infection and that the generation of in vivo protective immunity depended on the host lymphocyte subsets, including CD4 + T cells, CD8 + T cells, and B cells. Consistent with this, immunization with AdFKN/ Legionella /DC induced significantly higher levels of serum anti- Legionella antibodies of several isotypes than those induced by control immunizations. Further analysis of spleen cells from the immunized mice indicated that the AdFKN/ Legionella /DC immunization elicited Th1-dominated immune responses to L. pneumophila . These observations suggest that fractalkine may play an important role in the DC-mediated host defense against intracellular pathogens such as L. pneumophila .


  • Adenovirus Vector-Mediatedin VivoGene Transfer of OX40 Ligand to Tumor Cells Enhances Antitumor Immunity of Tumor-Bearing Hosts

    by Sita Andarini, Toshiaki Kikuchi, Mio Nukiwa, Prasenohadi Pradono, Takuji Suzuki, Shinya Ohkouchi, Akira Inoue, Makoto Maemondo, Naoto Ishii, Yasuo Saijo, et al.

    OX40 ligand (OX40L), the ligand for OX40 on activated CD4+ T cells, has adjuvant properties for establishing effective T-cell immunity, a potent effector arm of the immune system against cancer. The hypothesis of this study is that in vivo genetic engineering of tumor cells to express OX40L will stimulate tumor-specific T cells by the OX40L-OX40 engagement, leading to an induction of systemic antitumor immunity. To investigate this hypothesis, s.c. established tumors of three different mouse cancer cells (B16 melanoma, H-2b; Lewis lung carcinoma, H-2b; and Colon-26 colon adenocarcinoma, H-2d) were treated with intratumoral injection of a recombinant adenovirus vector expressing mouse OX40L (AdOX40L). In all tumor models tested, treatment of tumor-bearing mice with AdOX40L induced a significant suppression of tumor growth along with survival advantages in the treated mice. The in vivo AdOX40L modification of tumors evoked tumor-specific cytotoxic T lymphocytes in the treated host correlated with in vivo priming of T helper 1 immune responses in a tumor-specific manner. Consistent with the finding, the antitumor effect provided by intratumoral injection of AdOX40L was completely abrogated in a CD4+ T cell-deficient or CD8+ T cell-deficient condition. In addition, ex vivo AdOX40L-transduced B16 cells also elicited B16-specific cytotoxic T lymphocyte responses, and significantly suppressed the B16 tumor growth in the immunization-challenge experiment. All of these results support the concept that genetic modification of tumor cells with a recombinant OX40L adenovirus vector may be of benefit in cancer immunotherapy protocols.


  • Open Access

    Dendritic Cells Pulsed with Live and Dead Legionella pneumophila Elicit Distinct Immune Responses

    by Toshiaki Kikuchi, Takao Kobayashi, Kazunori Gomi, Takuji Suzuki, Yutaka Tokue, Akira Watanabe, Toshihiro Nukiwa

    Legionella pneumophila is the causative pathogen of Legionnaires’ disease, which is characterized by severe pneumonia. In regard to the pathophysiology of Legionella infection, the role of inflammatory phagocytes such as macrophages has been well documented, but the involvement of dendritic cells (DCs) has not been clarified. In this study, we have investigated the immune responses that DCs generate in vitro and in vivo after contact with L. pneumophila. Heat- and formalin-killed L. pneumophila, but not live L. pneumophila, induced immature DCs to undergo similar phenotypic maturation, but the secreted proinflammatory cytokines showed different patterns. The mechanisms of the DC maturation by heat- or formalin-killed L. pneumophila depended, at least in part, on Toll-like receptor 4 signaling or on Legionella LPS, respectively. After transfer to naive mice, DCs pulsed with dead Legionella produced serum Ig isotype responses specific for Legionella, leading to protective immunity against an otherwise lethal respiratory challenge with L. pneumophila. The in vivo immune responses required the Ag presentation of DCs, especially that on MHC class II molecules, and the immunity yielded cross-protection between clinical and environmental strains of L. pneumophila. Although the DC maturation was impaired by live Legionella, macrophages were activated by live as well as dead L. pneumophila, as evidenced by the up-regulation of MHC class II. Finally, DCs, but not macrophages, exhibited a proliferative response to live L. pneumophila that was consistent with their cell cycle progression. These findings provide a better understanding of the role of DCs in adaptive immunity to Legionella infection.